The global Pharmacovigilance Software Market was valued at USD 1.26 billion in 2025. It is estimated to reach USD 1.39 billion in 2026 and is projected to grow to USD 3.39 billion by 2036, at a CAGR of 9.3% during the forecast period. This report offers a detailed look at the market, covering the regulatory landscape, the technology landscape, the value chain, investment, partnership, and M&A activity, case studies, competitive activity, and future growth opportunities.
Pharmacovigilance software is used to collect, process, assess, and report adverse events and to monitor the safety of medicinal products and medical devices throughout their lifecycle. It includes adverse event case management, signal detection and management, aggregate and periodic reporting, risk management, literature and social media monitoring, and safety analytics and AI automation, delivered as software and services to pharmaceutical and biotechnology companies, CROs, device manufacturers, and regulators.
The FDA transition to the ICH E2B(R3) standard in 2026, rising adverse event case volumes, and the migration of safety systems to the cloud are driving demand, while vendors are introducing generative and agentic AI and the market is consolidating, as shown by the agreement of Dassault Systèmes to acquire ArisGlobal in July 2026. At the same time, implementation and validation costs and legacy lock-in shape the pace of change.
The report examines market drivers, restraints, opportunities, challenges, and trends, the regulatory landscape in the U.S., the EU, the U.K., Japan, China, and India, the technology landscape, the value chain, Porter's five forces, investment, partnership, and M&A activity, and case studies. It explains why safety analytics and AI automation, cloud deployment, SMEs, and biotechnology companies and CROs are growing faster than the overall market. It also provides market forecasts, segment-level insights, and regional analysis across 5 regions and 27 countries and sub-regions to support business, investment, and product decisions.
High implementation and validation costs and legacy system lock-in slow the pace of adoption and platform change. In addition, the validation and regulatory acceptance of AI, data privacy and residency requirements, and shortages of skilled PV and technology staff remain challenges.
AI-driven automation of case processing, demand from small and mid-sized biopharmaceutical companies, and the development of PV systems in emerging markets offer significant opportunities. Meanwhile, generative and agentic AI is entering production use, safety software is being consolidated into broader platforms, and real-world data is being integrated into signal detection.
Based on functionality, the market is segmented into adverse event case management, signal detection and management, aggregate and periodic reporting, risk management, literature and social media monitoring, and safety analytics and AI automation. In 2026, adverse event case management is expected to account for the largest share of the market, while safety analytics and AI automation is expected to grow the fastest.
Based on component, the market is segmented into software and services. In 2026, software is expected to account for the larger share of the market and to grow faster, driven by cloud subscriptions and AI modules.
Based on deployment mode, the market is segmented into cloud-based and on-premises. In 2026, cloud-based deployment is expected to account for the larger share and to grow faster, as legacy systems migrate to SaaS platforms.
Based on organization size, the market is segmented into large enterprises and small and mid-sized enterprises. In 2026, large enterprises are expected to hold the larger share, while SMEs are expected to grow faster, supported by affordable pre-configured cloud solutions.
Based on end user, the market is segmented into pharmaceutical companies, biotechnology companies, CROs and PV outsourcing providers, medical device manufacturers, and regulatory authorities and others. In 2026, pharmaceutical companies are expected to hold the largest share, while biotechnology companies and CROs are expected to grow the fastest.
In 2026, North America is expected to account for the largest share of the global market, driven by the size of the U.S. industry and the FDA transition to E2B(R3), with the U.S. as the largest country market in the world. In Europe, the U.K. is the largest market, slightly ahead of Germany.
Asia-Pacific is expected to grow the fastest during the forecast period, led by India, the fastest-growing country market in the world, while Japan is the largest market in the region and the second-largest in the world. In the Middle East & Africa, Israel is the largest market and Saudi Arabia is the fastest-growing, while in Latin America, Brazil is the largest market and Mexico is expected to grow the fastest.
The market is led by a small group of platform vendors. Based on 2025 market share, Oracle ranked first, followed by Veeva Systems, ArisGlobal, IQVIA, Qinecsa Solutions, and Ennov. Product launches and agreements and contracts are the main strategies, including agentic AI launches by ArisGlobal, Veeva, Oracle, and RxLogix, the go-live of UCB on the Veeva Safety Suite, and the agreement of Dassault Systèmes to acquire ArisGlobal.
The competitive benchmarking compares companies across functionalities, deployment models, and end users. Companies compete on cloud delivery, AI capabilities, platform breadth, migration support, validation, and price.
Key companies profiled in the report include Oracle Corporation (U.S.), Veeva Systems Inc. (U.S.), ArisGlobal LLC (U.S.), IQVIA Holdings Inc. (U.S.), Ennov (France), AB Cube (France), RxLogix Corporation (U.S.), Qinecsa Solutions (U.K.), Sarjen Systems Pvt. Ltd. (India), Clinevo Technologies (India), Cloudbyz (U.S.), and Biologit (Ireland).
Pharmacovigilance software is used to collect, process, assess, and report adverse events and to monitor the safety of medicinal products and medical devices throughout their lifecycle. It includes adverse event case management, signal detection and management, aggregate and periodic reporting, risk management, literature and social media monitoring, and safety analytics and AI automation, delivered as software and services to pharmaceutical and biotechnology companies, CROs, device manufacturers, and regulators.
The FDA transition to the ICH E2B(R3) standard in 2026, rising adverse event case volumes, and the migration of safety systems to the cloud are driving demand, while vendors are introducing generative and agentic AI and the market is consolidating, as shown by the agreement of Dassault Systèmes to acquire ArisGlobal in July 2026. At the same time, implementation and validation costs and legacy lock-in shape the pace of change.
The report examines market drivers, restraints, opportunities, challenges, and trends, the regulatory landscape in the U.S., the EU, the U.K., Japan, China, and India, the technology landscape, the value chain, Porter's five forces, investment, partnership, and M&A activity, and case studies. It explains why safety analytics and AI automation, cloud deployment, SMEs, and biotechnology companies and CROs are growing faster than the overall market. It also provides market forecasts, segment-level insights, and regional analysis across 5 regions and 27 countries and sub-regions to support business, investment, and product decisions.
Market Dynamics
Expanding regulatory reporting requirements, led by the FDA transition to E2B(R3), are the main force behind market growth. Rising adverse event case volumes, the growth of biotechnology pipelines, and the migration of safety systems to the cloud reinforce demand.High implementation and validation costs and legacy system lock-in slow the pace of adoption and platform change. In addition, the validation and regulatory acceptance of AI, data privacy and residency requirements, and shortages of skilled PV and technology staff remain challenges.
AI-driven automation of case processing, demand from small and mid-sized biopharmaceutical companies, and the development of PV systems in emerging markets offer significant opportunities. Meanwhile, generative and agentic AI is entering production use, safety software is being consolidated into broader platforms, and real-world data is being integrated into signal detection.
Segment Analysis
The report analyzes the market by functionality, component, deployment mode, organization size, end user, and geography, helping stakeholders identify the most promising growth opportunities.Based on functionality, the market is segmented into adverse event case management, signal detection and management, aggregate and periodic reporting, risk management, literature and social media monitoring, and safety analytics and AI automation. In 2026, adverse event case management is expected to account for the largest share of the market, while safety analytics and AI automation is expected to grow the fastest.
Based on component, the market is segmented into software and services. In 2026, software is expected to account for the larger share of the market and to grow faster, driven by cloud subscriptions and AI modules.
Based on deployment mode, the market is segmented into cloud-based and on-premises. In 2026, cloud-based deployment is expected to account for the larger share and to grow faster, as legacy systems migrate to SaaS platforms.
Based on organization size, the market is segmented into large enterprises and small and mid-sized enterprises. In 2026, large enterprises are expected to hold the larger share, while SMEs are expected to grow faster, supported by affordable pre-configured cloud solutions.
Based on end user, the market is segmented into pharmaceutical companies, biotechnology companies, CROs and PV outsourcing providers, medical device manufacturers, and regulatory authorities and others. In 2026, pharmaceutical companies are expected to hold the largest share, while biotechnology companies and CROs are expected to grow the fastest.
Regional Analysis
The report covers North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, spanning 27 countries and sub-regions. The regional analysis considers PV regulations, pharmaceutical and biotechnology industry structure, cloud readiness, data residency rules, and outsourcing activity.In 2026, North America is expected to account for the largest share of the global market, driven by the size of the U.S. industry and the FDA transition to E2B(R3), with the U.S. as the largest country market in the world. In Europe, the U.K. is the largest market, slightly ahead of Germany.
Asia-Pacific is expected to grow the fastest during the forecast period, led by India, the fastest-growing country market in the world, while Japan is the largest market in the region and the second-largest in the world. In the Middle East & Africa, Israel is the largest market and Saudi Arabia is the fastest-growing, while in Latin America, Brazil is the largest market and Mexico is expected to grow the fastest.
Competitive Landscape
The report provides a detailed review of the competitive landscape, covering key growth strategies, competitive benchmarking, the competitive dashboard, and market share analysis, together with profiles of leading companies including their financial performance, product portfolios, strategy and market position, strategic developments, and SWOT analyses.The market is led by a small group of platform vendors. Based on 2025 market share, Oracle ranked first, followed by Veeva Systems, ArisGlobal, IQVIA, Qinecsa Solutions, and Ennov. Product launches and agreements and contracts are the main strategies, including agentic AI launches by ArisGlobal, Veeva, Oracle, and RxLogix, the go-live of UCB on the Veeva Safety Suite, and the agreement of Dassault Systèmes to acquire ArisGlobal.
The competitive benchmarking compares companies across functionalities, deployment models, and end users. Companies compete on cloud delivery, AI capabilities, platform breadth, migration support, validation, and price.
Key companies profiled in the report include Oracle Corporation (U.S.), Veeva Systems Inc. (U.S.), ArisGlobal LLC (U.S.), IQVIA Holdings Inc. (U.S.), Ennov (France), AB Cube (France), RxLogix Corporation (U.S.), Qinecsa Solutions (U.K.), Sarjen Systems Pvt. Ltd. (India), Clinevo Technologies (India), Cloudbyz (U.S.), and Biologit (Ireland).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the global pharmacovigilance software market.
- Explains how E2B(R3) and other regulatory requirements, case volumes, cloud migration, and AI affect market growth.
- Identifies high-growth opportunities across functionality, component, deployment mode, organization size, end user, and region.
- Analyzes the regulatory and technology landscapes, the value chain, and investment and M&A activity shaping the market.
- Benchmarks leading companies based on their portfolios and market share.
- Supports product strategy, partnership and acquisition evaluation, investment planning, and market entry decisions.
- Delivers practical market insights for PV software vendors, implementation partners, pharmaceutical and biotechnology companies, CROs, device manufacturers, and investors.
Key Questions Answered
- How big is the global pharmacovigilance software market today, and how will it grow through 2036?
- How is the FDA transition to E2B(R3) driving demand for safety database upgrades and migrations?
- What are the main drivers, restraints, opportunities, and challenges shaping the industry?
- Which functionality, component, deployment mode, organization size, end-user, and regional segments will grow the fastest?
- How will AI automation change case processing and the structure of PV spending?
- How fast will safety systems move from on-premises to cloud platforms?
- Which regions and countries offer the most attractive business opportunities?
- Who are the leading companies in the market, and what strategies are they following?
- How will platform consolidation, including the Dassault Systèmes-ArisGlobal deal, reshape the competitive landscape?
Table of Contents
1. Introduction
2. Research Methodology
4. Market Overview
5. Pharmacovigilance Software Market, by Functionality
6. Pharmacovigilance Software Market, by Component
7. Pharmacovigilance Software Market, by Deployment Mode
8. Pharmacovigilance Software Market, by Organization Size
9. Pharmacovigilance Software Market, by End User
10. Pharmacovigilance Software Market, by Geography
11. Competitive Landscape
12. Company Profiles
13. Appendix
List of Tables
List of Figures
Companies Mentioned
- Oracle Corporation
- Veeva Systems Inc.
- ArisGlobal LLC
- IQVIA Holdings Inc.
- Ennov
- AB Cube
- RxLogix Corporation
- Qinecsa Solutions
- Sarjen Systems Pvt. Ltd.
- Clinevo Technologies
- Cloudbyz
- Biologit (Ireland).
